Clinical Pharmacokinetics and Pharmacodynamics
Syllabus, Master's level, 3FB225
- Education cycle
- Second cycle
- Main field(s) of study and in-depth level
- Drug Discovery and Development A1N, Pharmaceutical Sciences A1N
- Grading system
- Fail (U), Pass (G), Pass with distinction (VG)
- Finalised by
- The Educational Board of Pharmacy, 25 August 2022
- Responsible department
- Department of Pharmacy
150 credits, including 120 credits in biomedicine, biology, pharmaceutical sciences, chemistry and/or natural sciences/technology. Earlier studies should include 7.5 credits of pharmacokinetics and 7.5 credits of pharmacology.
Proficiency in Swedish and English equivalent to the general entry requirements for first-cycle (Bachelor's level) studies.
On completion of the course, the student will be able to
* analyse pharmacokinetic (PK) and pharmacodynamic (PD) information in clinical drug development.
* contribute at planning, design and analysis of clinical studies, from a PK and PD perspective.
* describe and interpret various types of variables and parameters that are used to measure and model drug effects.
* Explain PD models that describe disease progression with and without simultaneous drug treatment
* Apply PD models that describe the relationship between drug exposure and effect
* Review what a clinical trial simulation is and what information that is required to perform such a simulation
* Illustrate how models can contribute to adjustment of drug dosing at an individual level
* Orally present and discuss results, in proper English, and give constructive feedback to other participants
* Summarize scientific publications and a performed task in writing, in a format similar to a scientific report or scholarly journal
The course illustrates how PK and PD information can be used in clinical drug development with a focus on studies related to PK and/or PD. The course include presentation technique, , simulation of clinical studies, presentation and models for relationships between drug exposure, effect and models for disease progression, PK and PD aspects on study design and clinical trial simulation.
The course assumes full-time studies. The main part of the work takes place in groups (2-8 students per group, dependent on workshop and student numbers).
The teaching consists of lectures, workshops and demonstrations/exercises with software. Each workshop is a larger assignment that is reported joint in groups or presented in writing individually.
Compulsory parts of the course:
Certain in advance stated lectures and active participation in workshops.
During the course, continuous examinations are conducted. The course is divided into five parts that are examined through oral presentations (3 as 1.0 hp and 1 as 2.5 hp) and a written report (1 as 2.0 hp). Possibility to supplement failed compulsory parts can be given at the earliest at the next course date and only in case of a vacancy.
Re-examination is organised when necessary.
If there are special reasons for doing so, an examiner may make an exception from the method of assessment indicated and allow a student to be assessed by another method. An example of special reasons might be a certificate regarding special pedagogical support from the disability coordinator of the university.
Substituting and corresponding to 3FB053 or 3FB625, Clinical pharmacokinetics, pharmacodynamics and advanced course C.